Biotechnology firm Pharmaxis has appointed Gary Phillips as chief executive to replace Dr Alan Robertson who is stepping down.

Mr Phillips has been Pharmaxis’ chief operating officer for the past five years.

He takes up the position as chief executive immediately.

Mr Phillips will review the company’s operations to ensure that it remains commercially successful.

Pharmaxis chairman Malcolm McComas said the company was facing likely delays in the commercialisation of its drug to treat cystic fibrosis, Bronchitol, in the United States.

Pharmaxis is awaiting a response from the US Food and Drug Administration on the company’s application for marketing approval for Bronchitol to treat cystic fibrosis patients aged six and older.